Abstract Endocrine therapy resistance in estrogen receptor alpha positive (ERa?) breast cancers remains a major obstacle for maintaining efficacy of targeted therapies. We investigated the significance and the mechanisms involved in cMYC over-expression in a MCF7 derived panel of ERa? breast cancer cells which can proliferate in the absence of estrogen with different sensitivities to antihormone therapies. We show that all the resistant cell lines tested over-express cMYC as compared to parental MCF7 cells and its inhibition lead to the differential blocking of estrogen-independent proliferation in resistant cells. Further investigation of the resistant cell line, MCF7:5C, suggested transcriptional de-regulation of cMYC gene was responsible for its over-expression. Chromatin immunoprecipitation assay revealed markedly higher recruitment of phosphorylated serine-2 carboxy-terminal domain (CTD) of RNA polymerase-II at the proximal promoter of cMYC gene, which is responsible for transcriptional elongation of the cMYC RNA. The level of CDK9, a factor responsible for the phosphorylation of serine-2 of RNA polymerase II CTD, was found to be elevated in all the resistant cell lines. Pharmacological inhibition of CDK9 not only reduced the transcripts and the protein levels of cMYC in MCF7:5C cells but also selectively inhibited the estrogen-independent growth of all the resistant cell lines. This study describes the up-stream molecular events involved in the transcriptional over-expression of cMYC gene in breast cancer cells proliferating estrogen-independently and identifies CDK9 as a potential novel drug target for therapeutic intervention in endocrine-resistant breast cancers.
Introduction
Resistance to endocrine therapies (tamoxifen and aromatase inhibitors) represents a major clinical concern for the survivorship of the estrogen receptor positive breast cancer patients [1] [2] [3] . The majority of hormone receptor positive advanced breast cancer patients report disease progression within 2-3 years of endocrine therapy treatment [4] [5] [6] . Recent clinical studies have found over-expression of the cMYC oncogene and the genes regulated by cMYC as one of the major predictor in the aromatase inhibitor resistant breast cancers [7] [8] [9] whereas its over-expression is sufficient to confer resistance to anti-estrogens [10] . Besides endocrine resistance, cMYC oncoprotein have been found to regulate the expression of ''poor-outcome'' signature genes responsible for metastasis [11] . Gain of cMYC is also associated with the progression of invasive ductal carcinoma from the ductal carcinoma in situ [12] and amplification of cMYC in breast cancer is significantly associated with risk of relapse and death [13] . It is therefore appropriate to study the underlying molecular mechanisms which contribute to estrogen independence and acquired resistance to identify novel therapeutic targets for the endocrine therapy resistant breast cancers.
Although targeting cMYC represents an obvious therapeutic opportunity to block the growth of the resistant breast cancer cells, this has not been successful due to the lack of a drug-able domain in its 'basic helix-loop-helix' structure [14] . Additionally, unacceptable toxicity is associated with cMYC inhibition, as the protein is critically involved in proliferation and regeneration of normal adult tissues [15, 16] . Other approaches such as synthetic lethality [17] and modulating chromatin-dependent signal transduction have been used to circumvent direct targeting of cMYC [18] .
To determine the relevance and mechanism of cMYC over-expression in imparting estrogen-independence to the endocrine-resistant breast cancer cells, we used a panel of MCF7 ERa? breast cancer cells which are known to proliferate in the absence of estrogen and exhibit different sensitivities to the anti-hormone therapies. The different MCF7 cell line derivatives used were MCF7:5C [19] , MCF7:2A [20] , MCF7/LCC1 [21] , MCF7/LCC2 [22] , and MCF7/LCC9 [23, 24] . All these cells mimic aromatase inhibitor resistance as they can grow in an estrogendeprived condition. In addition, MCF7:5C and LCC2 cells are also resistant to anti-estrogens, 4-hydroxy-tamoxifen (4OHT) whereas LCC9 cells demonstrate resistance to 4OHT and fulvestrant. All these cell lines cells showed high expression of cMYC protein as compared to parent MCF7 cells and estrogen-independent growth of all the resistant cells was drastically inhibited by a cMYC inhibitor, 10058-F4 (F4). For focused studies, we chose MCF7:5C cells as we have extensive experience with this cell line and the LCC1, LCC2, and LCC9 cells showed modest estrogen stimulation of growth [21] [22] [23] despite being estrogen-independent. On the other hand MCF7:5C cells undergo apoptosis after estrogen treatment [25, 26] . This is a documented response clinically, following the development of anti-hormone resistance [27] .
This study dissects the upstream molecular mechanism involved in the transcriptional over-expression of cMYC oncogene in the endocrine-therapy resistant cells, which imparts estrogen-independence. In addition, we present CDK9 as a potential target for therapeutic intervention which can suppress the deregulated transcriptional overexpression of cMYC leading to complete inhibition of estrogen-independent proliferation of the endocrine-resistant breast cancer cells.
Materials and methods

Cell culture and reagents
Cell culture media were purchased from Invitrogen Inc. (Grand Island, NY, USA) and fetal calf serum (FCS) was obtained from HyClone Laboratories (Logan, UT, USA). The ERa? breast cancer cells MCF-7:WS8 (mentioned as MCF7) and estrogen-deprived MCF7:5C and MCF7:2A cells were derived from MCF7 cells obtained from the Dr. Dean Edwards, San Antonio, Texas as reported previously [19] . The MCF7/LCC1, LCC2, and LCC9 were obtained from the shared tissue culture facility of the Lombardi comprehensive cancer center. The cell lines were authenticated by DNA fingerprinting. All the cells except MCF7 cells were maintained in phenol red-free RPMI media (Invitrogen Inc., Grand Island, NY, USA) supplemented with 10 % charcoal dextran treated FCS, 6 ng/ml bovine insulin and penicillin and streptomycin. MCF7 cells were maintained in phenol red containing media with 10 % FCS. Three to four days prior to harvesting the MCF7 cells were cultivated in phenol red-free media containing 10 % charcoal dextran treated FCS. cMYC inhibitor, 10058-F4 was purchased from Sigma-Aldrich (St. Louis, MO, USA) and CDK9 inhibitor, CAN 508 (cat # 238811), was purchased from EMD Chemicals Inc. (San Diego, CA, USA). All the experiments were performed at least three times, in triplicate to confirm the results.
Cell growth assay
The cell growth assays were performed by measuring the total DNA per well in 24 well plates. Twenty to twenty five thousand cells were plated per well and treatment with indicated concentrations of compounds was started after 24 h, in triplicates. Media with specific treatments were changed every 48 h. The cells were harvested in hypotonic buffer solution followed by sonication after indicated time points. Total DNA was measured using a fluorescent dye (Hoechst 33258) in the DNA quantitation kit (Cat # 170-2480; Bio-Rad, Hercules, CA, USA) according to manufacturer's instructions.
RNA isolation and real time PCR
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and RNAeasy kit (Qiagen, Valencia, CA, USA) were used to isolate total RNA according to the manufacturer's instructions. Real-time PCR was performed as previously described [28] . Briefly, cDNA was generated from RNA using High capacity cDNA reverse transcription kits (Applied Biosystems, Foster City, CA, USA). Subsequently the cDNA was diluted and RT-PCR was performed using ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The change in expression of transcripts was determined as described previously using the ribosomal protein 36B4 mRNA as the internal control [28] . The primer sequences for the cMYC mRNA was 5 0 GCCAGCTCTCCACACATCAG 3 0 (forward); 5 0 TCTTGGCAGCAGGATAGTCCTT 3 0 (reverse).
Cell cycle analysis
The cells were treated with vehicle (0.1 % dimethyl sulfoxide), or cMYC inhibitor 10058-F4 at indicated concentrations and the cells were harvested and gradually fixed with 75 % EtOH on ice. Cells were stained with propidium iodide (PI), and analyzed using a fluorescence-activated cell sorter flow cytometer (Becton-Dickinson, San Jose, CA, USA), and the data analysis was performed by CellQuest software. All experiments were performed in triplicates and the graphs shown in the figures are representative of them.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed as described previously [28] with minor changes. Cells were cross-linked with paraformaldehyde and nuclei were isolated from cells which were re-suspended in SDS-lysis buffer followed by sonication and centrifugation. The supernatant were diluted 1:10 with ChIP dilution buffer. For the immuno-clearing and pull down of the immuno-complexes, protein A magnetic beads (Upstate cell signaling solutions, Temecula CA, USA) were linked to rabbit IgG raised against mouse IgM. This modification was essential to ensure effective pull-down by the anti-bodies against serine-2 phospho (Covance, Cat # MMS 129R; H5) and serine-5 phospho (Covance, Cat # MMS 134R; H14) RNA polymerase II. The beads bound to immuno-complexes were thereafter washed and precipitates were extracted twice using freshly made 1 % SDS and 0.1 M NaHCO 3 followed by decrosslinking. The DNA fragments were purified using Qiaquick PCR purification kit (Qiagen, Valencia, CA, USA). RT-PCR was performed using 2 ll isolated DNA, using primers specific for cMYC proximal promoter. The primers used (forward: GAGCAGCAGAGAAAGGGAGA; reverse: CAGCCGAGCACTCTAGCTCT) recognizes a region *150 bp upstream of transcription start site (TSS) of cMYC gene. The data is presented as percent input of starting chromatin input after subtracting the percent input pull down of the negative control (normal mouse IgM).
Western blotting
Whole cell protein lysates were isolated using RIPA buffer containing protease inhibitors (Roche Diagnostics, Mannheim, Germany) and phosphatase inhibitors I and II (EMD Chemicals Inc., San Diego, CA, USA). 15-20 lg of total protein was separated on the gels and transferred onto nitrocellulose membranes. The membranes were blocked with 5 % non-fat dry milk in tris-buffered saline and probed with primary and secondary antibodies. Specific bands were visualized using west-pico chemi-luminescence (Thermo-Fisher, Rockford, IL, USA). The antibodies used: cMYC (#5605), CDK9 (#2316), phospho-CDK9 (#2549), from Cell signaling Technologies (Danvers, MA); CTDP1 (#A301-172 A) Bethyl laboratories (Montgomery, TX, USA); beta-actin (#A5441; Sigma, St. Louis, MO). The bands were scanned and quantified using imageJ software (National Institutes of Health, Bethesda, MD, USA).
Relapse free survival (RFS) analysis
Kaplan-Meier plots for RFS analysis were generated using the on-line tool ''kmplot.com'' which has the annotated data set from various breast cancer studies and allows studying single gene association with RFS outcome of the patients using user defined parameters. To evaluate the effect of cMYC overexpression on RFS of endocrinetherapy versus chemotherapy treated breast cancer patients we compared the top 25 % patients expressing highest cMYC levels with the rest of the patient population. Two different plots were generated, one where the patients were treated with endocrine therapy (excludes chemotherapy) and the other with patients treated with chemotherapy (excludes endocrine-therapy). All other parameters were unchanged.
Statistics
Statistical significance of our data was assessed using the Student's t test wherever relevant. A p value of \0.05 was considered as statistically significant.
Results
Levels of cMYC and estrogen-independent growth of ERa? endocrine resistant breast cancer cells
We found that all the endocrine-therapy resistant breast cancer cells used in this study, namely, MCF7:5C, MCF7:2A, MCF7/LCC1, MCF7/LCC2, and MCF7/LCC9 cells overexpress cMYC mRNA (Fig. 1a) and protein ( S1b ) and fivefold higher proliferation over a 6 day period ( Supplementary Fig. S1a ).
To determine if the high levels of cMYC mRNA was due to the elevated transcriptional activity or stability of the transcripts we performed a pulse chase assay and found that the cMYC mRNA had a similar rate of degradation in MCF7 and MCF7:5C cells (Supplementary Fig. 3 ).
Inhibition or depletion of cMYC blocks estrogenindependent proliferation of ERa? endocrine resistant cells
We determined the functional role of cMYC over-expression in estrogen-independent growth of the endocrinetherapy resistant breast cancer cells by blocking the cMYC action using a pharmacological inhibitor 10058-F4 which has been shown to specifically inhibit actions of cMYC by blocking its interaction with MAX [29] and stabilizing the MYC monomer [30] . cMYC inhibition with 30 lM of 10058-F4 selectively inhibited 50-80 % of the estrogenindependent growth of all the resistant cells ( Fig. 2a) whereas only 18 % growth inhibition was observed in MCF7 cells. Further experiments with MCF7:5C cells showed that 10058-F4 was selectively able to inhibit its growth in a dose-dependent manner as compared to MCF7 cells over a 4 day period (Fig. 2b) . Cell cycle analysis confirmed that the decrease in proliferation resulted from a 57 % reduction in the 'S' phase cells of the MCF7:5C cells (Fig. 2c) . In comparison, there was only 6 % decrease in the 'S' phase cells of the parental MCF7 cells. We also used the targeted approach to confirm the role of cMYC in MCF7:5C cells, by depleting cMYC levels using short interfering RNA (siRNA). Two different siRNA against cMYC depleted the levels of its protein in MCF7:5C cells which led to 50-75 % reduction in the number of 'S' phase cells (Fig. 2d) with a concurrent inhibition of cell growth over a period of 4 days (Supplementary Fig. S2a ). Reduced phosphorylation of retinoblastoma protein ( Supplementary  Fig. S2b ) was also evident in the cells depleted of cMYC protein.
cMYC gene expression correlates with RFS in endocrine therapy but not chemotherapy treated patients
The Kaplan-Meier plots were generated for cMYC gene association with RFS of early breast cancer patients who received endocrine-therapy or chemotherapy only as an adjuvant treatment. We used the on-line tool (www.kmplot. com) which has a combined data set from various annotated breast cancer studies and can be used to study the association of a single gene with patients outcome using various user defined parameters [31] . The top 25 % percent highest cMYC expressing patients (top quartile) were compared with the rest of the 75 %. Kaplan-Meier plots Recruitment of phospho-serine-2 and phospho-serine-5 RNA polymerase II at the cMYC promoter in MCF7:5C and MCF7 Cells
To further determine the mechanism of steady-state transcriptional over-expression of the cMYC mRNA in MCF7:5C cells, we probed the proximal promoter of the cMYC gene (Fig. 4a) in terms of recruitment of phosphorylated serine-5 and phosphorylated serine-2 RNA polymerase II, which is responsible for the initiation and the elongation of the transcription of RNA, respectively. ChIP assay using phospho-specific RNA polymerase II antibodies revealed that in MCF7:5C cells the recruitment of serine-2 phosphorylated RNA polymerase II was more than threefold higher than parental MCF7 cells (Fig. 4b) . However, no difference was observed in the recruitment of serine-5 phosphorylated RNA polymerase II at the cMYC promoter in MCF7:5C and MCF7 cells (Fig. 4c) . We further confirmed that the total levels of phosphorylated serine-2 or serine-5 RNA polymerase was not different in MCF7:5C cells as compared to MCF7 cells (Fig. 4d) .
Levels of cyclin dependent kinase 9 (CDK9) and its role in estrogen-independent growth of endocrinetherapy resistant cells CDK9 is a major kinase which is responsible for the phosphorylation of serine-2 RNA polymerase II [32, 33] and the elongation of RNA transcripts [34] . We therefore examined the total CDK9 levels in the endocrine-therapy resistant cells and observed an over-expression in all the cells as compared to the MCF7 cells ( Supplementary Fig. 4Sa ). In MCF7:5C cells, the total as well as the phosphorylated CDK9 levels were elevated by 2.5 and 3.1 fold respectively (Fig. 5a) . We also observed a slight increase in the levels of CTDP/FCP1 protein in MCF7:5C cells, which is known to dephosphorylate CDK9 [32] (Fig. 5a) . Interestingly, FCP1 has also been reported to stimulate transcription elongation [35] . Next, we used a specific, potent, competitive inhibitor of CDK9, known as CAN 508 [36] to study the role of CDK9 in estrogen-independent growth of MCF7:5C cells and compared it with the parental MCF7 cells. A dose dependent effect was observed in MCF7:5C cells where 30 lM of CAN 508 compound completely inhibited its growth over a 6 day period (Fig. 5b) . Furthermore, 30 lM of CAN 508 drastically blocked the growth of all endocrine-therapy resistant breast cancer cells used in this study (Supplementary Fig. 4Sb ) whereas it had minimal growth inhibitory effect on the parental MCF7 cells.
Endocrine Therapy (excludes chemotherapy)
Chemotherapy (excludes endocrine therapy) (Fig. 6a) . This was followed by time dependent decline in cMYC protein levels (Fig. 6b) . Concomitant inhibition of serine-2 phosphorylated RNA polymerase II CTD was also observed within an hour of treatment (Fig. 6b) indicating its role in cMYC transcription. As evident, serine-5 phosphorylation of RNA polymerase II CTD was not much altered within 4 h of CDK9 inhibition. Although later time points showed marked reduction in serine-5 phosphorylation, along with serine-2 phosphorylation which was most likely due to secondary effects of CDK9 inhibition. Inhibition of CDK9 also completely blocked the phosphorylation of retinoblastoma (Rb) protein within 12 h of treatment ( Supplementary Fig.  S5 ) in the MCF7:5C cells.
Discussion
Accumulative evidence indicates that cMYC overexpression and subsequent genes up-regulated in breast cancers are associated with resistance to AIs [8] and antiestrogens [7, 9] . This study establishes the role and mechanism of cMYC regulation in the estrogen-independent growth of ERa?, endocrine-resistant breast cancer cells. All the resistant cell models used in this study are MCF7-derived cell lines. Importantly, MCF7 cells retain the ERa protein after acquiring endocrine therapy resistance which mimics the clinical scenario as 80 % of the endocrine-therapy resistant breast cancer patients are ERa positive [37] . Interestingly, despite the limited availability of cell lines, significant translational advances have occurred [24] . Based on our results, we decipher a novel mechanism of transcriptional over-expression of cMYC in resistant breast cancer cells (Fig. 6c) CTD at the promoter of cMYC gene. This, in turn, is responsible for the transcriptional elongation and overexpression of cMYC. Our analysis of the annotated breast cancer patient's database (Fig. 3) suggested that overexpression of cMYC correlates with the failure of endocrine therapy (but not chemotherapy) and eventual relapse of the disease. Ectopic overexpression of cMYC in MCF7 cells is reported to be sufficient to confer resistance to endocrine therapy [7, 10] . We observed elevated cMYC levels in the ERa?, endocrine therapy-resistant breast cancer cells (Fig. 1a, b) which proliferated in the absence of estrogen. A previous study has also reported high cMYC levels in long-term estrogen deprived cells [38] . Inhibition of cMYC or its depletion blocked the proliferation of the cells (Fig. 2a, Supplementary Fig. S2a ) demonstrating the critical role of cMYC overexpression in estrogen-independent growth of these resistant breast cancer cells. The reduction in 'S' phase cells (Fig. 2c, d ) was achieved by de-phosphorylation of tumor suppressor retinoblastoma (Rb) protein ( Supplementary Fig. S2b ) which is known to arrest the cells in G1 phase of the cell-cycle [39] .
Further, using a pulse chase assay, we ascertained that the high basal level of cMYC mRNA in the MCF7:5C cells was due to the high rate of transcription and not enhanced stability of the transcripts (Fig. S3) . Since therapeutic targeting of cMYC is not feasible, we studied the upstream factors responsible for cMYC transcriptional over-expression from its natural proximal promoter in the MCF7:5C cells. Transcription of cMYC gene is regulated at the elongation step by promoter-proximal pausing of RNA polymerase II in eukaryotes [40, 41] . Importantly, cMYC is a well-defined estrogen-regulated gene [42] and the estrogen-induced growth of the hormone responsive breast cancer cells is contingent upon the expression of cMYC gene in these cells as majority of growth related genes which are estrogen regulated are cMYC target [43] . In MCF7 cells, studies have demonstrated [44] that the proximal promoter of the cMYC gene is pre-loaded with RNA polymerase II which is phosphorylated at serine 5 of its CTD, in the absence of estrogen. However, phosphorylation of serine-2 of CTD of RNA polymerase II is needed to overcome the elongation block of the transcripts which is achieved after estrogen stimulation. Our findings are consistent. In MCF7 cells, we observed high levels of serine-5 phosphorylation, and low serine-2 phosphorylation of RNA polymerase II CTD at the cMYC promoter under basal conditions (Fig. 4b, c) . In contrast, under identical condition, the phosphorylation of serine-2 of CTD of RNA polymerase II is markedly elevated in MCF7:5C cells (Fig. 4a, b) which drives the higher transcriptional elongation of cMYC.
The kinase complex responsible for the phosphorylation of serine-2 of RNA polymerase II CTD and inducing transcriptional elongation is known as positive transcriptional elongation factor-b which is composed of CDK9 and cyclin T1 [45] [46] [47] . Our observation of higher levels of CDK9 in MCF7:5C cells (Fig. 5a ) and in other resistant breast cancer cells (Supplementary Fig. S4a ) strongly suggested that it is responsible for elevated serine-2 phosphorylation of RNA polymerase II CTD at the cMYC promoter of MCF7:5C cells. Indeed, using a pharmacological agent, CAN 508, which specifically inhibits CDK9 activity [36, 48] , the growth of MCF7:5C cells (Fig. 5b) as well as other endocrine therapy resistant MCF7 derived ERa ? breast cancer cells (Supplementary Fig. S4b) were selectively inhibited. This demonstrated that the estrogenindependent growth of the endocrine therapy resistant breast cancer cells was driven by CDK9. We further Total CDK9 levels and effect of its inhibition on estrogenindependent growth. a Protein levels of phospho and total CDK9 and CTDP1 was assessed using western blotting in MCF7 and MCF7:5C cells. The numbers above each band correspond to the fold change in protein levels versus MCF7 cells adjusted for beta actin levels for each sample. b Total DNA was measured to assess the growth of MCF7 and MCF7:5C cells after 2, 4, and 6 days of treatment with indicated doses of the CDK9 inhibitor, CAN508
confirmed that inhibition of CDK9 led to the reduction of cMYC mRNA levels within 1 h of treatment in MCF7:5C cells followed by the protein level (Fig. 6a, b) . The concurrent decrease in global serine-2 (but not serine-5) phosphorylation of RNA polymerase II CTD (Fig. 6b) suggested that CDK9 was responsible for cMYC transcriptional over-expression in the resistant cells. In addition, we confirmed that CDK9 inhibition reduced the level of phospho-Rb protein ( Supplementary Fig. S5 ) in a similar manner as cMYC depletion in the MCF7:5C cells. This supports our hypothesis that the growth suppressive effect of CDK9 inhibition reduces cMYC levels in the endocrinetherapy resistant breast cancer cells. Furthermore, we found that CDK9 or cMYC inhibition was not deleterious to the immortalized human epithelial cells (MCF10A) (Supplementary Fig. S6 ) indicating that CDK9 can be a potential novel therapeutic target. Since we did not detect any difference in the global level of serine-2 phosphorylated RNA polymerase II CTD between MCF7:5C and its parental MCF7 cells (Fig. 4d); further studies are required to establish the chromatin modifications at the cMYC promoter which ensue in the process of acquiring resistance. These changes are crucial as it allows the RNA polymerase II CTD to be hyperpermissive for serine-2 phosphorylation, thus ensuring elongation of the cMYC transcripts in the MCF7:5C cells. Intriguingly, recent reports have indicated that in hematologic malignancies bromo-domain containing protein 4 (BRD4), which has been known to recruit CDK9 and regulate serine-2 phosphorylation of RNA polymerase II [49, 50] , is involved in cMYC overexpression [18, 51] .
In this study, we have delineated the transcriptional mechanism of cMYC over-expression, endocrine-therapy resistant, ERa? breast cancer cells, and propose that recruitment of hyper-phosphorylated serine-2 RNA polymerase II at the cMYC promoter which is mediated by CDK9, is responsible for the estrogen independent proliferation of these cells. We therefore suggest that there will be a potential clinical benefit by using CDK9 inhibitors in the treatment of endocrine therapy resistant breast cancers. ) . b Protein levels of cMYC, phospho-serine-2, and serine-5 RNA polymerase II after inhibition of CDK9 by 100 lM of CAN508 for indicated time points. The numbers above each band correspond to the fold change in protein levels versus vehicle (Veh) treatment adjusted for beta actin levels for each sample. c The cartoon depicts our findings on the CDK9 mediated cMYC transcriptional regulation and its role in estrogen-independent growth of the MCF7:5C cells
